Targeting cancer's sweet spot: UGP2 as a therapeutic vulnerability. Academic Article uri icon

Overview

abstract

  • Understanding the mechanisms governing metabolic reprogramming that underlie potential vulnerabilities in cancer cells is key to developing novel therapeutic strategies. The catalytic enzyme UDP-glucose pyrophosphorylase 2 (UGP2) drives the production of UDP-glucose. Our recent work demonstrated the crucial role of UGP2 in cancer growth and its regulation of cellular metabolic processes.

publication date

  • October 27, 2021

Identity

PubMed Central ID

  • PMC8997258

Scopus Document Identifier

  • 85118293281

Digital Object Identifier (DOI)

  • 10.1080/23723556.2021.1990676

PubMed ID

  • 35419477

Additional Document Info

volume

  • 8

issue

  • 6